Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up After Strong Earnings

Tandem Diabetes Care, Inc. (NASDAQ:TNDM)’s share price gapped up prior to trading on Friday following a stronger than expected earnings report. The stock had previously closed at $18.52, but opened at $22.75. Tandem Diabetes Care shares last traded at $24.0340, with a volume of 1,091,677 shares.

The medical device company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.04. The company had revenue of $290.38 million for the quarter, compared to analyst estimates of $277.14 million. Tandem Diabetes Care had a negative return on equity of 73.97% and a negative net margin of 20.19%.The business’s revenue was up 15.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.01 EPS.

Tandem Diabetes Care News Roundup

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q4 results beat expectations: reported revenue of $290.4M (vs. ~$277M est.) and EPS of ($0.01) vs. consensus ($0.05) — a better-than-expected quarter that supports near-term revenue growth hopes. Q4 earnings summary
• Positive Sentiment: Company reported record quarterly sales and strong pump shipments (38,000 units), evidence of continued market demand for its insulin-delivery products. BusinessWire press release
• Positive Sentiment: Bank of America upgraded TNDM from Underperform to Neutral and raised its price target to $30 (up from $15), signaling bullish conviction from one major shop and creating upside narrative for the stock. Benzinga
• Neutral Sentiment: FY‑2026 revenue guidance was roughly in line with Street expectations (~$1.1B), so there were no big upward surprises in forward revenue targets; investors will watch execution to meet that guidance. Guidance details
• Neutral Sentiment: UBS kept a Hold rating with a $22 price target, reflecting tempered expectations despite the beat — this sustains mixed analyst views and limits consensus momentum. TipRanks / UBS note
• Negative Sentiment: UBS called out uncertainty from the company’s PayGo transition and competitive headwinds — these execution risks could pressure growth and margins if the transition slows adoption or increases churn. TipRanks / UBS commentary
• Negative Sentiment: Profitability and leverage remain concerns — negative net margin and return on equity plus elevated debt-to-equity may keep investors cautious until sustained profitability is visible. Zacks analysis

Wall Street Analysts Forecast Growth

TNDM has been the subject of a number of recent research reports. Piper Sandler reaffirmed a “neutral” rating and set a $21.00 price target (up previously from $14.00) on shares of Tandem Diabetes Care in a research report on Friday. Morgan Stanley set a $23.00 target price on shares of Tandem Diabetes Care and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. UBS Group reissued a “neutral” rating and issued a $22.00 target price on shares of Tandem Diabetes Care in a report on Friday. Wall Street Zen upgraded Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tandem Diabetes Care in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $25.50.

Hedge Funds Weigh In On Tandem Diabetes Care

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd lifted its stake in shares of Tandem Diabetes Care by 200.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,205 shares of the medical device company’s stock worth $27,000 after purchasing an additional 1,470 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in Tandem Diabetes Care by 80.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,330 shares of the medical device company’s stock worth $30,000 after acquiring an additional 593 shares during the period. Quarry LP lifted its holdings in shares of Tandem Diabetes Care by 2,597.1% during the third quarter. Quarry LP now owns 3,695 shares of the medical device company’s stock worth $45,000 after purchasing an additional 3,558 shares during the period. CWM LLC boosted its holdings in shares of Tandem Diabetes Care by 262.6% in the 2nd quarter. CWM LLC now owns 2,796 shares of the medical device company’s stock valued at $52,000 after acquiring an additional 2,025 shares during the last quarter. Finally, CoreCap Advisors LLC grew its position in Tandem Diabetes Care by 270.3% during the 3rd quarter. CoreCap Advisors LLC now owns 4,751 shares of the medical device company’s stock worth $58,000 after purchasing an additional 3,468 shares during the period.

Tandem Diabetes Care Stock Performance

The company has a quick ratio of 1.90, a current ratio of 2.44 and a debt-to-equity ratio of 2.33. The firm has a 50-day moving average of $20.85 and a two-hundred day moving average of $16.95. The company has a market capitalization of $1.63 billion, a PE ratio of -7.85 and a beta of 1.68.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.